By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

RESI is well-known for its vibrant partnering and high turnout of active investors, licensing partners and service providers focused on the early-stage life science community, but there is also an all-star line-up of quality educational content to help entrepreneurs on their fundraising journeys. Insightful investor panels will discuss key topics surrounding investment and partnership in specific areas of the life sciences and provide perspective on different investor types. There will also be live workshops focused on the most relevant issues that keep entrepreneurs up at night, imparted by experts in their fields.
Register for RESI for active partnering with a 3-day hybrid registration, or simply to partake in the amazing content being offered on June 5th with an Audience Access Pass. More Information Here
LSN NEW PRODUCT RELEASE – “Global Partnering Campaign (GPC), Fundraising & Licensing Partner Roadshow Management.”
Monday, June 5 | 8:00 – 8:30am ET; 12:00 – 12:30am ET
LSN will debut a leading-edge platform called the “Global Partnering Campaign (GPC), Fundraising & Licensing Partner Roadshow Management.” The GPC integrates LSN’s Investor and Licensing Partner Database and the Salesforce CRM.
Subscribing companies receive a vetted Global Target List (GTL) of likely partners garnered through one-on-one interviews with the LSN research team, which can be organized into three tiers of Investor Priority:
- Tier 1: Partner is matched on a specific mandate.
- Tier 2: Partner is matched on an opportunistic mandate seeking compelling technology assets.
- Tier 3: Partner is matched as a potential fit based on past or recent actions. This is where the numbers game comes into play.
Information on these profiles is automatically updated daily, and user outreach and tasks can be tracked intuitively with CRM components, including the following:
- Status of Outreach (Lead, Reviewing Materials, Call/Meeting Scheduled, etc.)
- Materials Sent (Executive Summary, Pitch Deck, etc.)
- Notes (NDA status, DD, and data room)
- Reporting (investor/licensing pipeline)
LSN customized this platform, leveraging years of experience as a broker/dealer helping early-stage life sciences companies attract capital. Fundraising is a numbers game, and as companies transition from the regional to the global arena, difficulty juggling outreach with many different companies and contacts worldwide is inevitable. Managing your fundraising campaign adroitly is essential, and with the GPC platform, LSN makes it simple. The GPC product is a game changer for early-stage startups seeking between $100K and $50M (Seed-Series B).
Please join the GPC presentation on managing your global partnering campaign.
Presenter:
Karen Deyo, Director of Product, Israel BD, Life Science Nation
The NIH as a Technology Development and Commercialization Partner
Monday, June 5 | 9:00 – 9:50am ET
The National Institutes of Health (NIH) is a resource that companies should consider to bolster their pipeline or solve a development problem. Join us for a live webinar with representatives from various groups within the NIH for an opportunity to learn how your organization can partner with the NIH to get products to market. Participants will learn: • The NIH is more than basic research. Economic development is part of the mission. • That companies, entrepreneurs, and other buy-side stakeholders – not just academia – can partner with the NIH. • Why industry partnerships are mutually beneficial for companies and the NIH. • How companies have worked with the NIH (success stories and partnership examples). • Next steps – points of contact, partnering mechanisms, licensing.
Presenters:
- Michael Salgaller, PhD, Supervisory Specialist, Technology Transfer Center, National Cancer Institute, National Institutes of Health (Moderator)
- Tara L. Kirby, Ph.D., Director, Office of Technology Transfer, National Institutes of Health
- Vladimir Popov, Ph.D., Chief Innovation Officer, Center for Innovation and Strategic Partnerships, Frederick National Laboratory for Cancer Research
- Anthony D. Saleh, Ph.D., Chief Executive Officer and Founder, miRecule, Inc.
Tales from the Road
Monday, June 5 | 10:00 – 10:50am ET
The industry has quickly adapted to a “new normal” – entrepreneurs and investors meet virtually over digital platforms to discuss potential investment opportunities, and it is not uncommon to see entrepreneurs raise capital from investors they have never met before in person. That said, there is no doubt that the fundraising journey continues to be challenging for many. In this panel, you will be able to hear fellow entrepreneurs share their experiences, from successes to challenges. This panel will discuss the following topics and more: • What are some of the greatest challenges entrepreneurs have faced, especially during the pandemic, and how were they overcome? • How did entrepreneurs identify investors that fit their technology? • What are some misconceptions entrepreneurs had about the early-stage investment landscape? Furthermore, entrepreneurs will share unique tips and insights they have gained from their fundraising experiences, and how others can work their way towards a more successful campaign.
Presenters:
- Greg Mannix, VP of International Business Development, Life Science Nation (Moderator)
- Ross Bundy, Co-founder and CEO, CRISPR QC
- Brian DellaValle, CEO, GLX Analytix
- Robert Rioux, CEO, theraGI
- Martha Shadan, Board Member, MedExecWomen
Negotiating Term Sheets
Monday, June 5 | 11:00 – 11:50am ET
This interactive workshop, organized and led by McDermott Will & Emery, will provide wisdom to early-stage CEOs and management on the latest trends in term sheets, with a focus on founder and management equity opportunities. The workshop will cover common issues of concern to entrepreneurs (valuation/dilution, liquidation preference, board makeup, protective provisions, anti-dilution). Experts from the legal, investment and entrepreneurial community will discuss the interplay of financing milestones in the term sheet discussion.
Presenters:
- Mark Mihanovic, Partner, McDermott Will & Emery
- Richard Smith, Counsel, McDermott Will & Emery
- Nancy Briefs, President & CEO, AltrixBio, Inc.
- Isaac Stoner, MBA, CEO, Octagon Therapeutics
- Wasim Malik, Managing Partner, Iaso Ventures
IP Considerations for Start-ups
Monday, June 5 | 1:00 – 1:50pm ET
Intellectual Property is an absolutely key issue for life science startups to understand in order to make the right decisions along the journey toward commercialization. This session, led by Burns & Levinson Partner Shawn Foley, will address the main aspects of a good IP strategy that will help guide life science entrepreneurs be better prepared as they move their technologies forward.
Presenter:
Shawn P. Foley, Partner, Burns & Levinson
Maximizing Pre-Clinical Development Success for VC-Backed Start-Ups Through CRO Partnerships
Monday, June 5 | 2:00 – 2:50pm ET
Preclinical development is often complex and non-linear. You need to coordinate several CROs, CDMOs and an army of consultants while project managing it all. Join our workshop as we discuss best practices in finding and engaging with the right CRO partners to increase your chance of getting to IND faster, with greater success. Choosing the right CRO partner not only saves you time, money and whole lotta nerves, but gets the attention of investors. Investors appreciate well thought out, fully integrated product development plans that clearly identify value inflection milestones, contingencies, and mitigation strategies. The right CRO partner will make you look good in the eyes of investors—make sure to take advantage of that!
Presenters:
- Marta New, PhD, MBA, CEO, Radyus Research
- Omar Khalil, PhD, General Partner, Sante Ventures
- Livija Deban, CSO, Prokarium Ltd
- John Foglesong, MBA, CEO, Grannus Therapeutics
- Paul Tebbey, PhD, MBA, Board Member & Advisor, Radyus Research
Fundraising Strategy and Messaging for First-Time CEOs
Monday, June 5 | 3:00 – 3:50pm ET
Join the Life Science Nation team to master the art of fundraising from Seed to Series B. Discover the essential insights and strategies to avoid common pitfalls and maximize your fundraising success. Learn about early-stage life science investors and uncover the 10 fundraising myths that can waste your time and hinder your progress. Additionally, we will share tips on Branding & Messaging, develop a strong brand identity and create high-quality collateral that engages potential investors. Communicate your message clearly and concisely to help investors decide quickly if you’re a potential fit. Gain the essential knowledge and skills to shape a strong fundraising strategy and increase your chances of securing the capital you need. This workshop is a must-attend for first-time CEOs and seasoned entrepreneurs seeking fundraising success.
Presenters:
- Claire (Chae-Kyeong) Jeong, VP, Investor Research & Asia BD, Life Science Nation
- Candice He, VP, Business Development & Global Investment Strategist, Life Science Nation
Company Valuation for Fundraising
Monday, June 5 | 4:00 – 4:50pm ET
Valuation is a key aspect of fundraising. An average value assumption for each company in a specific financing stage just does not do it anymore. For entrepreneurs, as for investors, its important to understand the value drivers of a company. We are looking at the financing trends of the last years, discuss dos and don’ts when speaking with investors and look at how to value a life science company with no revenues. Agenda: • Overview financing trends • Which is the right investor • Dos and don’ts • Company valuation approaches • Conclusion
Presenters:
- Patrik Frei, Founder & CEO, Venture Valuation AG, Switzerland
- Gergely Ivanyi, PharmD, Senior Consultant, Venture Valuation

Like this:
Like Loading...